Literature DB >> 16338267

Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction.

Giuseppe De Luca1, Arthur C Maas, Harry Suryapranata, Jan Paul Ottervanger, Jan C A Hoorntje, A T Marcel Gosselink, Jan-Henk Dambrink, Menko-Jan de Boer, Arnoud W J van 't Hof.   

Abstract

BACKGROUND: The analysis of ST-segment resolution is a well established and easy method to assess myocardial perfusion after reperfusion therapy for ST-segment elevation myocardial infarction (STEMI). The aim of the current study was to identify an easy and practical instrument for patients' prognostic stratification after angioplasty for STEMI by the use of only postprocedural ST-segment analysis.
METHODS: Our population is represented by a total of 1286 patients treated with primary angioplasty for STEMI. Residual ST-segment elevation and deviation were analyzed at 3 hours after revascularization. One-year follow-up data were collected prospectively in all patients.
RESULTS: Patients with impaired ST-segment normalization were older, with larger prevalence of diabetes, anterior infarction, hypertension, signs of heart failure at presentation, lower rate of postprocedural thrombolysis in myocardial infarction 3 flow, myocardial blush grades 2 to 3, and successful reperfusion. A linear relationship was found between both residual cumulative ST-segment elevation and deviation with 1-year mortality. At multivariate analysis, postprocedural residual cumulative ST deviation (RR 1.31, 95% CI 1.06-1.63, P = .014), but not residual cumulative ST elevation (RR 0.95, 95% CI 0.55-1.67, P = .87), was an independent predictor of 1-year mortality. Furthermore, we found that residual cumulative ST-segment deviation provides better prognostic information (area receiver operating characteristic [ROC] = 0.733) than ST-segment elevation resolution (area ROC = 0.636) or ST-segment deviation resolution (area ROC = 0.660) in terms of 1-year mortality. These data were confirmed for both anterior and nonanterior infarct location.
CONCLUSION: This study showed that postprocedural residual cumulative ST-segment deviation is an independent prognostic parameter in patients treated with primary angioplasty, providing even better prognostic information than ST-segment resolution.

Entities:  

Mesh:

Year:  2005        PMID: 16338267     DOI: 10.1016/j.ahj.2005.01.056

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation.

Authors:  Giuseppe De Luca; Maurits T Dirksen; Christian Spaulding; Henning Kelbæk; Martin Schalij; Leif Thuesen; Bas van der Hoeven; Marteen A Vink; Christoph Kaiser; Carmine Musto; Tania Chechi; Gaia Spaziani; Luis Salvador Diaz de la Llera; Vincenzo Pasceri; Emilio Di Lorenzo; Roberto Violini; Harry Suryapranata; Gregg W Stone
Journal:  Clin Res Cardiol       Date:  2014-04-01       Impact factor: 5.460

Review 2.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

3.  Absolute eosinophils count and the extent of coronary artery disease: a single centre cohort study.

Authors:  Monica Verdoia; Alon Schaffer; Ettore Cassetti; Gabriella Di Giovine; Paolo Marino; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

4.  Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.

Authors:  Matthew W Sherwood; David A Morrow; Benjamin M Scirica; Songtao Jiang; Christoph Bode; Nader Rifai; Robert E Gerszten; C Michael Gibson; Christopher P Cannon; Eugene Braunwald; Marc S Sabatine
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

5.  Circumflex artery-related acute myocardial infarction: limited ECG abnormalities but poor outcome.

Authors:  S Rasoul; M J de Boer; H Suryapranata; J C A Hoorntje; A T M Gosselink; F Zijlstra; J P Ottervanger; J H E Dambrink; A W J van 't Hof
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

6.  Combined Assessments of Biochemical Markers and ST-Segment Resolution Provide Additional Prognostic Information for Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Jong Shin Woo; Jin Man Cho; Soo Joong Kim; Myeong Kon Kim; Chong Jin Kim
Journal:  Korean Circ J       Date:  2011-07-30       Impact factor: 3.243

7.  Does pre-angiography Total ST-segment resolution reliably predict spontaneous reperfusion of the infarct-related artery in patients with acute myocardial infarction?

Authors:  Zongsheng Guo; Xinchun Yang
Journal:  BMC Cardiovasc Disord       Date:  2019-11-26       Impact factor: 2.298

8.  Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration.

Authors:  Youlan L Gu; Marieke L Fokkema; Marthe A Kampinga; Bart J G L de Smet; Eng S Tan; Ad F M van den Heuvel; Felix Zijlstra
Journal:  Trials       Date:  2009-09-28       Impact factor: 2.279

9.  Clinical Predictors of Incomplete ST-Segment Resolution in the Patients With Acute ST Segment Elevation Myocardial Infarction.

Authors:  So Ra Park; Young Ran Kang; Myeng Ki Seo; Min Kyeng Kang; Jong Hyen Cho; Yon Jung An; Chung Hwan Kwak; Sek Jae Hwang; Young Hun Jung; Jin Yong Hwang
Journal:  Korean Circ J       Date:  2009-08-27       Impact factor: 3.243

10.  High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study.

Authors:  Mohammed A Balghith
Journal:  Heart Views       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.